All In Biotech

Drug Trial Radar · NCT06500637

TB006 for Autism Spectrum Disorder

A Multi-center Double Blind Placebo Controlled Study to Assess the Safety and Efficacy of TB006 for Improving Core Symptoms in Adults With Autism Spectrum Disorder

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Aug 3, 2024

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Rossignol Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Autism Discovery and Treatment Foundation
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.

Conditions

  • Autism Spectrum Disorder

Interventions

  • TB006Drug

    TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Childhood Autism Rating Scores (CARS)Time frame: Baseline, Week 8 and Week 14

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Rossignol Medical Center

    Phoenix, Arizona · Recruiting

  • Rossignol Medical Center

    Aliso Viejo, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.